DDInter893 DDInter927
Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxis of malaria in regions where chloroquine resistance is unlikely. It was developed during World War II as a derivative of [quinacrine] with less severe side effects. Chloroquine and hydroxychloroquine are both being investigated for the treatment of SARS-CoV-2. **The FDA emergency use authorization for hydroxychloroquine and [chloroquine] in the treatment of COVID-19 was revoked on 15 June 2020.** Hydroxychloroquine was granted FDA approval on 18 April 1955.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Hydroxychloroquine {u} (Compound) resembles {v} (Compound) Chloroquine
Hydroxychloroquine {u} (Compound) resembles {v} (Compound) Amodiaquine
Hydroxychloroquine {u} may lead to a major life threatening interaction when taken with {v} Primaquine
Hydroxychloroquine {u} (Compound) binds {v} (Gene) TLR9
Hydroxychloroquine {u} (Compound) upregulates {v} (Gene) PAK1
Hydroxychloroquine {u} (Compound) downregulates {v} (Gene) TES
Hydroxychloroquine {u} (Compound) causes {v} (Side Effect) Vomiting
Hydroxychloroquine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Hydroxychloroquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aprepitant
Hydroxychloroquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Iodide I-131
Hydroxychloroquine (Compound) resembles Chloroquine (Compound)
Hydroxychloroquine (Compound) resembles Amodiaquine (Compound)
Hydroxychloroquine may lead to a major life threatening interaction when taken with Primaquine
Hydroxychloroquine (Compound) binds TLR9 (Gene)
Hydroxychloroquine (Compound) upregulates PAK1 (Gene)
Hydroxychloroquine (Compound) downregulates TES (Gene)
Hydroxychloroquine (Compound) causes Vomiting (Side Effect)
Hydroxychloroquine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant
Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131